Biocure Technology Inc. (BICTF)
| Market Cap | 797.22K +8.5% |
| Revenue (ttm) | n/a |
| Net Income | -1.62M |
| EPS | -0.08 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,000 |
| Open | 0.0100 |
| Previous Close | 0.0014 |
| Day's Range | 0.0100 - 0.0100 |
| 52-Week Range | 0.0012 - 0.0159 |
| Beta | 3.77 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 23, 2026 |
About Biocure Technology
Biocure Technology Inc. engages in a mineral exploration property project. The company was founded in 2005 and is headquartered in Vancouver, Canada. [Read more]
News
Biocure Technology Inc. enters into Definitive Share Exchange Agreement to acquire Glorious Success Limited
VANCOUVER, British Columbia – TheNewswire - August 12, 2026 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) announces, further to its press release dated June 22, 2026, that it has en...
Biocure Technology Inc. Announces Adoption of Semi-Annual Reporting
Vancouver, B.C. – TheNewswire - May 8, 2026 ‐ Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the “ Company” or “Biocure”) announces the adoption of semi-annual financial reporting. This news rele...
CSE Bulletin: Consolidation - Biocure Technology Inc. (CURE.X)
Toronto, Ontario--(Newsfile Corp. - le 23 octobre/October 2024) - Biocure Technology Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consoli...
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
TÜBINGEN, Germany and MUNICH, Germany, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atriva Therapeutics GmbH (“Atriva”) is pleased to disclose the signing of an exclusive letter agreement, dated September 14, 2...
Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that it has entered into an exclusive letter agreement date...
Biocure Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 25, 2022) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and inv...
Biocure Corporate Update and Financing
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and ...
Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia ("CLL") and Solid Tumor Cancers and Intent to Apply for Patents
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2021) - BioCure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (FSE: 1WH) ("BioCure" or the "Company") is pleased to provide the following corpora...
BioCure Technology Inc. Lists on the Frankfurt Stock Exchange and Completion of Issuer Sponsored Research Report
Vancouver, British Columbia--(Newsfile Corp. - August 3, 2021) - BioCure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (FSE: 1WH) (CURE or the Company) - BioCure Technology Inc. ("BioCure" or the "Compa...
BioCure Technology Inc. Announces New President, Appointment of Capital Markets Advisor and Grant of Stock Options
Vancouver, British Columbia--(Newsfile Corp. - July 22, 2021) - BioCure Technology Inc., (CSE: CURE) (OTCQB: BICTF) (CURE or the Company) is pleased to announce that Björn Cochlovius, Ph.D, Assoc.Prof...
BioCure Technology Inc. Announces Closing of Financing
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2021) - BioCure Technology Inc. (CSE: CURE) ("BioCure" or the "Company") announces that it has successfully closed a non-brokered private placem...
BiocurePharm, Korea (BPK) Signs MOU With Symbasis GmbH to Develop CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL)
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) (CURE or the Company) BiocurePharm, Korea (BPK), a subsidiary of Biocure Technolog...
BiocurePharm, Korea ("BPK") Announces the Submission of IND Application for Phase 1 Trial of CD19 CAR-T Therapy
Vancouver, British Columbia--(Newsfile Corp. - December 30, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure ...